R 5780
Alternative Names: R-5780Latest Information Update: 30 Jan 2023
At a glance
- Originator Rise Therapeutics
- Class Antineoplastics; Immunotherapies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Jan 2023 R 5780 is available for licensing as of 03 Jan 2023. https://risetherapeutics.com/capabilities
- 03 Jan 2023 Preclinical trials in Cancer in USA (PO) Before January 2023 (Rise Therapeutics pipeline, January 2023)
- 03 Jan 2023 Rise Therapeutics plans clinical trials in Cancer (PO, Capsule)